Viral Hepatitis

You have full text access to this OnlineOpen article

Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?†

  1. George V. Papatheodoridis1,‡,*,
  2. Emanuel K. Manesis1,
  3. Spilios Manolakopoulos1,
  4. Ioannis S. Elefsiniotis2,
  5. John Goulis3,
  6. John Giannousis1,
  7. Antonios Bilalis4,
  8. Georgia Kafiri5,
  9. Dimitrios Tzourmakliotis4,
  10. Athanasios J. Archimandritis1

Article first published online: 10 JUL 2008

DOI: 10.1002/hep.22518

Issue

Hepatology

Hepatology

Volume 48, Issue 5, pages 1451–1459, November 2008

Additional Information

How to Cite

Papatheodoridis, G. V., Manesis, E. K., Manolakopoulos, S., Elefsiniotis, I. S., Goulis, J., Giannousis, J., Bilalis, A., Kafiri, G., Tzourmakliotis, D. and Archimandritis, A. J. (2008), Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?. Hepatology, 48: 1451–1459. doi: 10.1002/hep.22518

Author Information

  1. 1

    2nd Department of Internal Medicine, Athens University Medical School, “Hippokration” General Hospital of Athens, Athens, Greece

  2. 2

    University Department of Internal Medicine, “Helena Venizelou” Hospital, Athens, Greece

  3. 3

    4th Department of Medicine, Aristotelian University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

  4. 4

    Department of Gastroenterology, Polyclinic General Hospital of Athens, Athens, Greece

  5. 5

    Department of Pathology, “Hippokration” General Hospital of Athens, Athens, Greece

  1. ‡

    fax: (30)-210-7706871

*2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas. Sophias Ave., 115 27 Athens, Greece

  1. †

    Potential conflict of interest: Dr. Papatheodoridis is a consultant for, advises, is on the speakers' bureau of, and received grants from Gilead Sciences, Roche, and Novartis. He is a consultant and advises Bristol-Myers Squibb. Dr. Manolakopoulos is a consultant, advises, is on the speakers' bureau of, and received grants from Gilead. He is a consultant for and received grants from Roche. He is a consultant for, advises, and received grants from Schering-Plough. He advises Bristol-Myers Squibb.

Publication History

  1. Issue published online: 28 OCT 2008
  2. Article first published online: 10 JUL 2008
  3. Accepted manuscript online: 10 JUL 2008 12:00AM EST
  4. Manuscript Accepted: 29 JUN 2008
  5. Manuscript Received: 13 FEB 2008

Funded by

  • Center for Control and Prevention of Diseases, Ministry of Health, Greece

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (163K)

References

  • 1
    Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52–61.
    Direct Link:
  • 2
    Hadziyannis SJ, Papatheodoridis GV. Hepatitis Be antigen negative chronic hepatitis B—natural history and treatment. Semin Liver Dis 2006; 26: 130–141.
  • 3
    Pawlotsky J-M, Bastie A, Lonjon I, Remire J, Darthuy F, Soussy C-J, et al. What techniques should be used for routine detection and quantification of HBV DNA in clinical samples? J Virol Methods 1997; 65: 245–253.
  • 4
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001; 120: 1828–1853.
  • 5
    Keeffe EB, Dieterich DT, Han S-HB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.
  • 6
    Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507–539.
    Direct Link:
  • 7
    Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001; 80: 63–71.
    Direct Link:
  • 8
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 9
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002; 36: 263–270.
  • 10
    Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2007; 8: 167–178.
  • 11
    Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15: 434–441.
    Direct Link:
  • 12
    Chu C-J, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. HEPATOLOGY 2002; 36: 1408–1415.
  • 13
    Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001; 34: 1225–1241.
    Direct Link:
  • 14
    Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87–106.
  • 15
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857–861.
    Direct Link:
  • 16
    Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666–676.
  • 17
    Manesis E, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98: 2261–2267.
  • 18
    Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760–767.
  • 19
    Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. HEPATOLOGY 2007; 46: 1057–1070.
    Direct Link:
  • 20
    Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 311–321.
    Direct Link:
View Full Article (HTML) Get PDF (163K)